189 related articles for article (PubMed ID: 8642281)
1. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
Huang AY; Bruce AT; Pardoll DM; Levitsky HI
J Exp Med; 1996 Mar; 183(3):769-76. PubMed ID: 8642281
[TBL] [Abstract][Full Text] [Related]
2. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.
Fu TM; Ulmer JB; Caulfield MJ; Deck RR; Friedman A; Wang S; Liu X; Donnelly JJ; Liu MA
Mol Med; 1997 Jun; 3(6):362-71. PubMed ID: 9234241
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells.
Doe B; Selby M; Barnett S; Baenziger J; Walker CM
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8578-83. PubMed ID: 8710913
[TBL] [Abstract][Full Text] [Related]
4. Gene vaccination with naked plasmid DNA: mechanism of CTL priming.
Corr M; Lee DJ; Carson DA; Tighe H
J Exp Med; 1996 Oct; 184(4):1555-60. PubMed ID: 8879229
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
6. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L
J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283
[TBL] [Abstract][Full Text] [Related]
7. Recognition of disparate HA and NS1 peptides by an H-2Kd-restricted, influenza specific CTL clone.
Kuwano K; Reyes VE; Humphreys RE; Ennis FA
Mol Immunol; 1991; 28(1-2):1-7. PubMed ID: 1707132
[TBL] [Abstract][Full Text] [Related]
8. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
Schoenberger SP; Jonges LE; Mooijaart RJ; Hartgers F; Toes RE; Kast WM; Melief CJ; Offringa R
Cancer Res; 1998 Jul; 58(14):3094-100. PubMed ID: 9679976
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
Chung SW; Cohen EP; Kim TS
Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
[TBL] [Abstract][Full Text] [Related]
11. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens.
Lenz LL; Butz EA; Bevan MJ
J Exp Med; 2000 Oct; 192(8):1135-42. PubMed ID: 11034603
[TBL] [Abstract][Full Text] [Related]
12. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
[TBL] [Abstract][Full Text] [Related]
13. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
Huang AY; Golumbek P; Ahmadzadeh M; Jaffee E; Pardoll D; Levitsky H
Science; 1994 May; 264(5161):961-5. PubMed ID: 7513904
[TBL] [Abstract][Full Text] [Related]
14. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
16. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
[TBL] [Abstract][Full Text] [Related]
17. Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells.
Miyazono Y; Kamogawa Y; Ryo K; Furukawa T; Mitsuhashi M; Yamauchi K; Kameoka T; Hayashi N
J Gastroenterol Hepatol; 1999 Oct; 14(10):997-1003. PubMed ID: 10530496
[TBL] [Abstract][Full Text] [Related]
18. Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells.
Kos FJ; Müllbacher A
Eur J Immunol; 1992 Jun; 22(6):1595-601. PubMed ID: 1376266
[TBL] [Abstract][Full Text] [Related]
19. Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen.
He XS; Chen HS; Chu K; Rivkina M; Robinson WS
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7274-8. PubMed ID: 8692982
[TBL] [Abstract][Full Text] [Related]
20. Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant.
Isobe H; Moran T; Li S; Young A; Nathenson S; Palese P; Bona C
J Exp Med; 1995 Jan; 181(1):203-13. PubMed ID: 7528768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
